ClinicalTrials.gg
CompletedNCT04770597MICHUpdated May 11, 2021

Monitors to Improve Indoor Carbon Dioxide (CO2) Concentrations in the Hospital

An interventional study of Aranet4 Home CO2 monitor in Healthcare Associated Infection, sponsored by Imelda Hospital, Bonheiden. Completed at 1 site in Belgium. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by Imelda Hospital, Bonheiden · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Sex
All
01

Study summary

Ventilation with fresh outdoor air has recently gained considerable attention as a means to reduce the potential risk of indoor aerosol transmission of respiratory pathogens such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19). Commercial carbon dioxide (CO2) monitors are increasingly used in schools, long-term care facilities, offices and public buildings to monitor indoor ventilation. However, no formal evidence is available to support the effectiveness of feedback from CO2 monitoring devices. Moreover, modern hospitals have superior indoor air quality control systems.

The aim of this prospective pilot randomized controlled trial (RCT) is to evaluate whether CO2 monitoring devices would be useful as a means to further maintain lower indoor CO2 concentrations in hospitals.

Read the detailed description

In this pilot, randomized, sham-controlled open-label RCT, hospital rooms will be fitted with Aranet4 Home CO2 sensors.

Each device will continuously measure indoor CO2 concentrations at 1-minute intervals during 4 time periods:

  1. Baseline: staff blinded to CO2 levels displayed on sensor

2-3. Sham/Intervention period: sensors on the same ward will be randomized to placebo (sensor not showing CO2 levels to staff) or Intervention (sensor displaying CO2 levels to staff) in a cross-over design

  1. Post-intervention phase (3 weeks post-intervention): staff blinded to CO2 levels

Each measurement period will consist of 7 days with no washout period.

Our primary hypothesis is that CO2 sensors will record less time (minutes) with elevated CO2 levels during the intervention period, compared to the Sham periods. However, carry-over effects will be investigated by comparing the Intervention periods to the Baseline and Post-intervention phases.

Note [February 27, 2021]: due to technical problems with the Aranet4 device Bluetooth connection, outcome data will be analyzed according to measurement data at 2-5 minute intervals (measurements can be made every minute, but data cannot be downloaded with the current version of the app due to technical problems).

02

Conditions studied

  • Healthcare Associated Infection

Browse trials for

Keywords

  • Indoor air quality
  • Carbon dioxide
  • Ventilation
03

In context

Cross Infection

287 studies on the registry are indexed under Cross Infection; 47 are open to participants now.

This study's enrollment of 12 is below the median of 193 across 170 interventional studies indexed under Cross Infection.

Browse Cross Infection studies →

Lead sponsor

Imelda Hospital, Bonheiden is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Double-bed hospital rooms

Exclusion criteria

Exclusion Criteria:

  • Unoccupied rooms
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Intervention

    CO2 values on sensor visible to staff

    Device: Aranet4 Home CO2 monitor

  • Sham comparator
    Sham control

    CO2 values on sensor not visible to staff

    Device: Aranet4 Home CO2 monitor

Interventions

  • DeviceAranet4 Home CO2 monitor

    The sensor is placed in the room at a height between 1 and 2 meters and not near the window or door.

06

What researchers measure

Primary outcomes

  1. Time >800 ppm CO2

    Time/day (in minutes/24h) measuring \>800 ppm CO2

    Time frame: 7 days/time period (pre-, active/sham and post-intervention)

Secondary outcomes

  1. Time >1000 ppm CO2

    Time/day (in minutes/24h) measuring \>1000 ppm CO2

    Time frame: 7 days/time period (pre-, active/sham and post-intervention)

  2. Time >1400 ppm CO2

    Time/day (in minutes/24h) measuring \>1400 ppm CO2

    Time frame: 7 days/time period (pre-, active/sham and post-intervention)

  3. Daily peak CO2 concentration [in ppm]

    Daily peak CO2 concentration \[in ppm\]

    Time frame: 7 days/time period (pre-, active/sham and post-intervention)

Other outcomes

  1. Staff-rated feasibility on a 10-point Likert scale [0-10, with 10 indicating better outcome]

    How feasible is it to use CO2 sensors to monitor indoor air quality in hospital? Anonymous online survey during the post-intervention phase

    Time frame: 7 days

  2. Staff-rated preference on a 10-point Likert scale [0-10, with 10 indicating better outcome]

    Would you prefer to use CO2 sensors to monitor indoor air quality in hospital in the future? Anonymous online survey during the post-intervention phase

    Time frame: 7 days

07

Study locations

1 site
  • Imelda Hospital
    Bonheiden, 2820, Belgium
08

References and documents

Publications

  • Laurent MR, Frans J. Monitors to improve indoor air carbon dioxide concentrations in the hospital: A randomized crossover trial. Sci Total Environ. 2022 Feb 1;806(Pt 3):151349. doi: 10.1016/j.scitotenv.2021.151349. Epub 2021 Oct 30. PubMed 34728206 ↗

Individual participant data

Plan to share: Yes — The full set of sensor data will be made available to established investigators upon simple request.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Data will be available upon fulltext print publication in a peer-reviewed journal, for a duration of at least 10 years.

Access criteria: Simple e-mail request to the corresponding author by an established scientific investigator

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in May 2021, 2 months.

Of 59 non-industry interventional studies with no phase under Cross Infection, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 2 months is below that.

Counting every sponsor, half of 61 studies reached it within 16 months; a quarter within 7 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2021
First posted
Feb 25, 2021
StartActual
Feb 21, 2021
Primary completionActual
May 2, 2021
CompletionActual
May 2, 2021
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04770597
Lead sponsor
Imelda Hospital, Bonheiden
Responsible party
Michaël R Laurent, MD PhD (Principal Investigator, Imelda Hospital, Bonheiden) — Principal investigator
First posted
Feb 25, 2021
Start date
Feb 21, 2021
Primary completion
May 2, 2021
Completion
May 2, 2021
Last update
May 11, 2021

Study contacts

Michaël R Laurent, MD PhD
principal investigator · Geriatrics Department, Imelda Hospital Bonheiden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion